Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;47(6):692-701.
doi: 10.1055/s-0040-1718925. Epub 2020 Dec 21.

Why, Whom, and How to Screen for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism

Affiliations
Review

Why, Whom, and How to Screen for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism

Gudula J A M Boon et al. Semin Thromb Hemost. 2021 Sep.

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is considered a long-term complication of acute pulmonary embolism (PE). Diagnosing CTEPH is challenging, as demonstrated by a considerable diagnostic delay exceeding 1 year, which has a negative impact on the patient's prognosis. Dedicated screening CTEPH strategies in PE survivors could potentially help diagnosing CTEPH earlier, although the optimal strategy is unknown. Recently published updated principles for screening in medicine outline the conditions that must be considered before implementation of a population-based screening program. Following these extensive principles, we discuss the pros and cons of CTEPH screening, touching on the epidemiology of CTEPH, the prognosis of CTEPH in the perspective of emerging treatment possibilities, and potentially useful tests and test combinations for screening. This review provides a modern perspective on CTEPH screening including a novel approach using a simple noninvasive algorithm of sequential diagnostic tests applied to all PE survivors.

PubMed Disclaimer

Conflict of interest statement

G.J.A.M.B. reports grants from Dutch Heart Foundation, outside the submitted work. M.V.H. reports grants from ZonMW Dutch Healthcare Fund and Aspen, and grants and personal fees from Boehringer Ingelheim, Pfizer-BMS, Bayer Health Care, and Daiichi-Sankyo, outside the submitted work. F.A.K. reports grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi Sankyo, MSD, Actelion, Netherlands Thrombosis Foundation, and Dutch Heart Foundation, outside the submitted work.

Similar articles

Cited by